Is Herbalife profitable in 2026?

Yes. Herbalife posted Q1 2026 net income of $61.9 million on net sales of $1.317 billion (+7.8% YoY) as of March 31, 2026, its third straight quarter of YoY growth. FY2025 net income was $228.3 million, down from $254.3 million in FY2024.

Could AI replace Herbalife's distributors?

AI-driven nutrition coaching apps threaten Herbalife's core personalized-advice value prop, but as of May 2026 Herbalife's own AI platform, Pro2col, remains in beta with no revenue counted in FY2026 guidance, so no confirmed replacement has happened yet.

Is Herbalife's weight-management business threatened by GLP-1 drugs like Ozempic?

Herbalife's brief flags GLP-1 drugs as a structural threat to its weight-management category (vendor-claimed), prompting a March 2026 pivot to position itself as a 'GLP-1 companion' via the $150 million Bioniq acquisition, with rollout expected later in 2026.

Herbalife (NYSE: HLF) is publicly traded with no controlling parent; Vanguard Group held roughly 10.13% as of January 30, 2026. It is incorporated in the Cayman Islands with operating headquarters in Los Angeles.

Is Herbalife's stock down a lot?

Yes. As of July 23, 2026, shares traded near $11.76-$12.37, down from a 52-week high of $20.40 and far below the all-time high of $61.77, giving a market cap of roughly $1.22-1.26 billion.

Has Herbalife faced regulatory trouble?

Herbalife paid a $200 million FTC settlement in 2016 requiring it to tie distributor rewards to retail sales, a $122 million FCPA settlement in August 2020 over China bribery, and a $12.5 million distributor class-action settlement in 2023.

Consumer brands · United States

Herbalife Ltd.

herbalife.com ↗

Herbalife sells weight-management and nutrition products through a global network of independent distributors.

Losing its protection

Assessed 23 July 2026 · Evidence as of 23 July 2026

The structural protection is eroding.

On the recordSince 23 July 2026 · Checkable from August 5, 2026 · Every call on the record Checkpoint: Q2 2026 earnings, testing a fourth straight quarter of sales growth

The call

Herbalife's distributor army is recovering and its Bioniq/Pro2col pivot is unproven, while GLP-1 drugs keep eating into the category it sells against.

Herbalife makes weight-loss and nutrition shakes sold by millions of independent distributors worldwide. The company is under attack from prescription drugs like Ozempic that work better for weight loss than pills and shakes, and nobody can copy or replace those drugs. The one thing that could save Herbalife is if its new artificial intelligence nutrition platform and biomarker testing actually work at scale and get real customers buying it, but that has not happened yet and there is no money from it in the company's forecasts.

Why

AI pressure: AI-driven nutrition coaching apps (Zoe, Levels, MyFitnessPal AI, ChatGPT-based advisors). Free or cheap AI coaching can replace the personalized advice distributors give, cutting the reason to buy through a person. Could AI do the core job? Only partly.

Bigger players: Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound). GLP-1 drugs are already pulling people out of the weight-management category Herbalife depends on, and Herbalife makes none of them. Could a giant copy it? Yes, easily.

What protects it. A 4.5 million person distributor network across 95 countries that took decades to build and is hard to copy quickly.

What would change this call

Herbalife's Q2 2026 earnings on August 5, 2026 show a fourth straight quarter of YoY sales growth. would confirm distributor and sales recovery is durable, not a one-time bounce.
Bioniq and Pro2col report measurable distributor-sold revenue after their 'later 2026' rollout. would show the AI/biomarker pivot is generating real income beyond the MLM channel.
Herbalife's debt leverage ratio falls toward 2.9x in 2026 per S&P's projected path. would show the company is deleveraging as planned rather than falling behind covenant targets.

Key numbers

FY2025 net sales $5.04B, up 0.89% (2025-12-31)
Q1 2026 net sales +7.8% YoY to $1.317B (2026-03-31)
Distributor count rose after 12 quarters of decline (2026-05-06)

Named risks

GLP-1 weight-loss drugs structurally displacing Herbalife's core weight-management category. Severity: high
Recurring MLM regulatory exposure: FTC ($200M, 2016), FCPA ($122M, 2020), distributor class actions (2023). Severity: high
Leverage must fall to S&P's 2.9x (2026) and 2.5x (2027) targets or rating/stock pressure resumes. Severity: medium
Pro2col and Bioniq remain unshipped-at-scale with zero revenue in FY2026 guidance as of May 2026. Severity: medium
Heavy insider selling by executives including COO in May 2026 signals caution on near-term stock. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Novo Nordisk / Eli Lilly (GLP-1 drugs)	losing to	GLP-1 drugs shipped and structurally eating weight-management category, cited as of 2026-03
Amway	contesting	Larger direct-selling rival competing for same global distributor pool as of 2026-05
Nu Skin	contesting	Peer MLM at ~$1.49B revenue also pursuing digital personalization, per MarketBeat 2026-07-11
USANA Health Sciences	contesting	Premium-positioned MLM peer competing for same distributor recruits, 2026-07
AI nutrition-coaching apps (Zoe, Levels, ChatGPT-based advisors)	gaining on	Commoditizing personalized nutrition advice Herbalife historically sold via distributors

Questions people ask

Is Herbalife profitable in 2026?: Yes. Herbalife posted Q1 2026 net income of $61.9 million on net sales of $1.317 billion (+7.8% YoY) as of March 31, 2026, its third straight quarter of YoY growth. FY2025 net income was $228.3 million, down from $254.3 million in FY2024.
Could AI replace Herbalife's distributors?: AI-driven nutrition coaching apps threaten Herbalife's core personalized-advice value prop, but as of May 2026 Herbalife's own AI platform, Pro2col, remains in beta with no revenue counted in FY2026 guidance, so no confirmed replacement has happened yet.
Is Herbalife's weight-management business threatened by GLP-1 drugs like Ozempic?: Herbalife's brief flags GLP-1 drugs as a structural threat to its weight-management category (vendor-claimed), prompting a March 2026 pivot to position itself as a 'GLP-1 companion' via the $150 million Bioniq acquisition, with rollout expected later in 2026.
Who owns Herbalife?: Herbalife (NYSE: HLF) is publicly traded with no controlling parent; Vanguard Group held roughly 10.13% as of January 30, 2026. It is incorporated in the Cayman Islands with operating headquarters in Los Angeles.
Is Herbalife's stock down a lot?: Yes. As of July 23, 2026, shares traded near $11.76-$12.37, down from a 52-week high of $20.40 and far below the all-time high of $61.77, giving a market cap of roughly $1.22-1.26 billion.
Has Herbalife faced regulatory trouble?: Herbalife paid a $200 million FTC settlement in 2016 requiring it to tie distributor rewards to retail sales, a $122 million FCPA settlement in August 2020 over China bribery, and a $12.5 million distributor class-action settlement in 2023.

Timeline

2026-07-13Named to TIME's America's Best Companies 2026 list
2026-05-22Raised FY2026 guidance: net sales growth 1.5-5.5%, adjusted EBITDA $675M-$705M
2026-05-06Q1 2026 results: net sales $1.317B (+7.8% YoY), third straight growth quarter
2026-04-29Completed $1.45 billion senior secured debt refinancing, saving ~$45M/year
2026-03-26Announced Bioniq acquisition for up to $150 million
2026-02-24S&P upgraded Herbalife credit rating, leverage path to 2.5x by 2027
2026-02-18FY2025 results reported; Ronaldo bought 10% Pro2col stake for $7.5M
2024-03Launched Herbalife Premier League distributor incentive program
2020-08-28Paid $122 million FCPA settlement over China bribery
2016Paid $200 million FTC settlement, restructured distributor rewards

Revision history

23 July 2026

First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.

In the same band

PVH VF Kering